NUWELLIS INC (NUWE)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.78+6.29%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · NUWE
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on increasing Aquadex system placements, utilization, and recurring circuit revenue, especially in pediatrics and critical care segments.
Stated as a priority in 2 of last 2 quarters. Revenue grew from $1.9M in 2025-Q1 to $2.4M in 2026-Q1, and nine consoles were sold in 2026-Q2 versus three in 2025-Q2, expanding the installed base. Management has reiterated focus on growing recurring revenue and Aquadex utilization, and the trajectory is delivering.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Focus on increasing installed base and utilization of Aquadex, building recurring circuit revenue.”
“Revenue growth driven by system placements and utilization of Aquadex therapy.”
Continue to enhance gross margin by adjusting pricing, optimizing product mix, and transitioning to contract manufacturing.
Stated in 2 of last 2 quarters. Gross margin improved from 56% in 2025-Q2 to 76% in 2026-Q2, and was 70.1% in 2026-Q1, driven by pricing, product mix, and contract manufacturing transition. Management's focus on margin expansion is reflected in these improvements, indicating delivering progress.
“Gross margin improved to 76%, reflecting pricing, product mix, and contract manufacturing.”
“Gross margin improved to 70.1%, reflecting improved pricing, product mix, and contract manufacturing.”
Secure financing to improve liquidity and support strategic initiatives through 2027.
Stated in 2 of last 2 quarters. The company raised $6.0M in June 2026 and approximately $6.7M in July 2026, increasing cash from $2.2M in 2026-Q1 to $3.9M in 2026-Q2, extending cash runway through Q2 2027. Management's capital raise priorities are delivering as planned.
“Raised $6.0 million in June offering and $6.7 million in July financing and warrant exercises.”
“No debt as of March 31, 2026; cash and equivalents approximately $2.2 million.”
Finalize acquisition and integrate Rendiatech's kidney function monitoring technology into product portfolio.
Stated in 2 of last 2 quarters. The acquisition of Rendiatech was completed in 2026-Q1 and integration progressed with deferred consideration liabilities recorded at $313K by 2026-Q2. Management has maintained focus on this strategic growth priority, showing delivering progress.
“Deferred consideration from Rendiatech acquisition recorded; intangible assets recognized.”
“Completed acquisition of Rendiatech, adding automated kidney-function monitoring capabilities.”
Manage executive leadership change with appointment of new CEO to guide company strategy and execution.
Newly stated in 2026-Q2. The company appointed Mike McCormick as CEO effective June 30, 2026, marking a leadership transition. This priority is recent with no prior quarters stating it, so trajectory is not yet established.
“Appointed Mike McCormick as President and CEO, effective June 30, 2026.”
Over the trailing year it converted 0.65x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
20 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.